Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity.

Journal: Nature communications
Published Date:

Abstract

Prime editing (PE) is a precise tool for introducing genetic mutations in eukaryotes. Extending the efficient editing scope and mitigating undesired byproducts are possible. We introduce reverse PE (rPE), a SpCas9-directed variant that enabled DNA editing at the 3' direction of HNH-mediated nick site. The rPE leveraging nCas9-D10A and rPE gRNA targeting the 5' direction of HNH-mediated nick site inscribes genetic alterations, achieving a reverse editing window and potentially high fidelity. HNH and reverse transcriptase engineered using protein language models in conjunction with La facilitate circular erPEmax and erPE7max, achieving editing efficiency up to 44.41% without nick gRNA or positive selection. Furthermore, our findings underscore the capability of rPE in inserting functionally enhanced variant (PIK3CD) for cell therapy. By expanding the editing scope and enhancing genomic manipulability, rPE represents a meaningful advancement in prime editing, improving its utility for research and therapeutic applications.

Authors

  • Chao Yang
    Translational Institute for Cancer Pain, Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences (Xinhua Hospital Chongming Branch), Shanghai 202155, P. R. China.
  • Qingxiao Fang
    Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Mengyu Li
    Department of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Jin Zhang
    Department of Otolaryngology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
  • Rui Li
    Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.
  • Tianxing Zhou
    Department of Bioinformatics, Faculty of Science, The University of Melbourne, Victoria 3010, Australia.
  • Keshan Wang
    Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Jie Deng
    Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, 1653 W. Congress Pkwy, Chicago, IL 60612, USA. Electronic address: Jie_deng@rush.edu.
  • Xiuchao Wang
    Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Chongbiao Huang
    Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Yukuan Feng
    Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Xiaoping Zhang
    China Academy of Chinese Medicine Sciences, Beijing, 100070, China.
  • Lei Shi
  • Changhao Bi
    Tianjin Institute of Industrial Biotechnology, Chinese Academy of Science, Tianjin 300308, China.
  • Xueli Zhang
    Center for Systems Biology, Soochow University, Suzhou 215006, Jiangsu, China.
  • Jun Yu
  • Jihui Hao
    Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. haojihui@tjmuch.com.